March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were ...

Xenon Pharmaceuticals (XENE) stock soared 40% after Phase 3 trial data for azetukalner exceeded expectations in focal onset seizures. FDA filing set for Q3 2026.

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

Having a single seizure doesn't mean you have epilepsy. Epilepsy is diagnosed if you've had at least two unprovoked seizures at least 24 hours apart. Unprovoked seizures don't have a clear cause.

Patients can spend anywhere from several days to several weeks in an epilepsy monitoring unit with electrodes protruding from holes drilled in their skulls. This is intracranial EEG, and it is now ...

SAN DIEGO — Certain musical elements within songs — especially when tied to emotional memories — may trigger a rare form of epilepsy known as musicogenic epilepsy, new research suggested The term ...